

Prof. SALİH SAYGIN EKER

Personal Information

Email: saygineker@uludag.edu.tr

Web: <https://avesis.uludag.edu.tr/saygineker>

International Researcher IDs

ORCID: 0000-0003-4629-8669

Publons / Web Of Science ResearcherID: Q-9477-2019

Yoksis Researcher ID: 158349

Education Information

Expertise In Medicine, Bursa Uludağ University, TIP FAKÜLTESİ, Dahili Tıp Bilimleri Bölümü, Turkey 1999 - 2004

Undergraduate, Trakya University, Tıp Fakültesi, Turkey 1993 - 1999

Research Areas

Medicine

Academic Titles / Tasks

Professor, Bursa Uludağ University, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ, 2018 - Continues

Associate Professor, Bursa Uludağ University, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ, 2011 - Continues

Assistant Professor, Bursa Uludağ University, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ, 2010 - 2011

Academic and Administrative Experience

Head of Department, Bursa Uludağ University, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ, 2018 - 2021

Courses

PSİKOTİK BOZUKLUKLAR, Undergraduate, 2017 - 2018

PSİKİYATRİK ACİLLER, Undergraduate, 2017 - 2018

ÖZKİYİM, Undergraduate, 2017 - 2018

Advising Theses

Eker S. S., Öz anlayış, psikolojik dayanıklılık ve benlik saygısının meme kanseri tanısı alıp mastektomi uygulanmış olan hastalarda ve sağlıklı gönüllülerde depresyon ve anksiyete düzeyleriyle ilişkisi, Expertise In Medicine, E.ÇAKAR(Student), 2023

Eker S. S., Depresyon, anksiyete ve bilinçli farkındalık arasındaki ilişkinin incelenmesi, Postgraduate, M.KUŞLUVAN(Student), 2022

Eker S. S., Tip 2 diyabet hastalarında tıknırcasına yeme bozukluğu ve gece yeme sendromu sıklığı; depresyon ve glisemik kontrol ile ilişkisi, Expertise In Medicine, Y.KORKMAZ(Student), 2022

Eker S. S., Ankilozan spondilit tanılı hastalarda hastalık aktivitesi, yaşam kalitesi, depresyon, anksiyete ile internetten hastalıkları araştırma motivasyonlarının değerlendirilmesi, Expertise In Medicine, O.ALP(Student), 2022

EKER S. S., Examining pet ownership in relation to depression and anxiety, Postgraduate, M.Asel(Student), 2020

Eker S. S., İki uçlu bozukluk-depresif atak ve majör depresif bozukluk tanılı hasta gruplarının psikososyal işlevsellik açısından karşılaştırılması, Expertise In Medicine, H.GENÇER(Student), 2020

Eker S. S., Şizofreni hastalarında dürtüsellik, sigara bağımlılığı, bakım veren külfeti ilişkisinin incelenmesi, Expertise In Medicine, B.GÜNDOĞAN(Student), 2019

EKER S. S., The examination of marital satisfaction between individuals with a psychiatric diagnosis and individuals without psychiatric diagnosis, Postgraduate, S.Fatalizade(Student), 2019

Eker S. S., Özkıym girişiminde bulunmuş ve bulunmamış olan major depresif bozukluk tanılı hastaların intihar düşüncesi, kaygı, umutsuzluk ve işlevsellik düzeyleri açılarından karşılaştırılması, Expertise In Medicine, H.KALE(Student), 2018

Eker S. S., Remisyon dönemi bipolar affektif bozuklukta akıl teorisi işlev bozukluğu, Expertise In Medicine, M.OĞUZHAN(Student), 2015

Eker S. S., Distimik bozuklukta kronik ağrı belirtileri, Expertise In Medicine, B.ESRA(Student), 2014

Eker S. S., Bipolar bozukluk depresif epizod ve unipolar depresyon tanılı hastalarda serum beyin kaynaklı nörotrofik faktör (BDNF) düzeyleri, Expertise In Medicine, Ü.SARIKAVAKLI(Student), 2011

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Antipsychotic-Treated Schizophrenia Patients Develop Inflammatory and Oxidative Responses Independently From Obesity: However, Metabolic Disturbances Arise From Schizophrenia-Related Obesity**
Emre S., Asli S., Sener M., EKER S. S., Esma S.
Human Psychopharmacology, vol.39, no.6, 2024 (SCI-Expanded)
- II. **Exploring the Personality Characteristics of Rhinoplasty Patients: Perfectionism, Rumination, and Self-Compassion**
Mete U., Demir U. L., Güllülü R. A., Eker S. S., Duman F., Altun N.
AESTHETIC PLASTIC SURGERY, 2024 (SCI-Expanded)
- III. **ACUTE PSYCHOSIS FOLLOWING COVID-19 INFECTION: A CASE REPORT**
GÜLLÜLÜ R. A., EKER S. S., SARANDÖL A.
PSYCHIATRIA DANUBINA, vol.34, no.1, pp.177-178, 2022 (SCI-Expanded)
- IV. **Comparison of the burdens of caregivers of patient with bipolar disorder-I and schizophrenia patient**
Hanci N., SARANDÖL A., Eker S. S., AKKAYA C.
ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY, vol.19, no.5, pp.451-458, 2018 (SCI-Expanded)
- V. **Can serum level of BDNF be used as a biomarker in distinction between the depressive episodes of bipolar disorder and recurrent major depressive disorder?**
EKER S. S., Sarikavakli U., CANGÜR Ş., AKKAYA C.
ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY, vol.18, no.2, pp.108-112, 2017 (SCI-Expanded)
- VI. **First-episode psychosis is associated with oxidative stress: Effects of short-term antipsychotic treatment**
SARANDÖL A., SARANDÖL E., Acikgoz H. E., EKER S. S., AKKAYA C., DİRİCAN M.
PSYCHIATRY AND CLINICAL NEUROSCIENCES, vol.69, no.11, pp.699-707, 2015 (SCI-Expanded)
- VII. **The efficacy of flupenthixol decanoate in bipolar disorder patients who have no sufficient remission with existing treatments**
EKER S. S., AKKAYA C., Pirincci E., CANGÜR Ş., KIRLI S.

ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY, vol.16, no.5, pp.364-367, 2015 (SCI-Expanded)

- VIII. **Investigating the relationship between pain and major depressive disorder in terms of depressive symptoms**
EKER S. S., Eker O. C., KIRLI S., ÖZKAYA G., Baykal B. E., AKKAYA C.
ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY, vol.16, no.4, pp.231-237, 2015 (SCI-Expanded)
- IX. **Relationship between Antidepressant Prescription Rates and Features of Schizophrenic Patients and Its Outcome in Schizophrenia Treatment**
Hanci N., Eker O. C., Miraloglu O., Uslu M. A., ÖZKAYA G., EKER S. S.
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, vol.52, no.1, pp.64-68, 2015 (SCI-Expanded)
- X. **Can BDNF and IL-2 be indicators for the diagnosis in schizophrenic patients with depressive symptoms?**
EKER S. S., Yavasci E. O., CANGÜR Ş., KIRLI S., Sarandol E.
ACTA NEUROPSYCHIATRICA, vol.26, no.5, pp.291-297, 2014 (SCI-Expanded)
- XI. **Increased plasma agmatine levels in patients with schizophrenia**
Uzbay T., GÖKTALAY G., Kayir H., Eker S. S., SARANDÖL A., Oral S., Buyukuysal L., Ulusoy G., KIRLI S.
JOURNAL OF PSYCHIATRIC RESEARCH, vol.47, no.8, pp.1054-1060, 2013 (SCI-Expanded)
- XII. **The Predictors of Remission in Major Depressive Disorder**
AKKAYA C., EKER S. S., SARANDÖL A., Cangur S., KIRLI S.
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, vol.50, no.2, pp.122-129, 2013 (SCI-Expanded)
- XIII. **Ziprasidone and Tardive Dystonia: A Case Report and Literature Review**
Turan A. B., AKKAYA C., EKER S. S., SARANDÖL A., Karli N.
KLINIK PSIKOFARMAKOLOJİ BULTENİ-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, vol.21, no.3, pp.242-245, 2011 (SCI-Expanded)
- XIV. **The Effects of Reboxetine and Venlafaxine on ECG Variables in Depressed Patients**
EKER S. S., AKKAYA C., Cangur S., Yuvanc U., SARANDÖL A., KIRLI S.
KLINIK PSIKOFARMAKOLOJİ BULTENİ-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, vol.21, no.1, pp.11-17, 2011 (SCI-Expanded)
- XV. **Early-versus late onset dysthymic disorder: clinical characteristics, symptom profile and social adaptation**
EKER S. S., AKKAYA C., Cangur S., SARANDÖL A., Yavasci E. O., Sarikavakli U., KIRLI S.
ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY, vol.12, no.1, pp.49-54, 2011 (SCI-Expanded)
- XVI. **Comparison of The Efficacy and Safety of Sertraline, Reboxetine, and Venlafaxine in Patients with Major Depressive Disorder: A Pooled Analysis of Four Randomized, Open-Label Trials**
Akkaya C., Kirli S., EKER S. S., Cangur S., Canbazoglu M., Sarandol A.
KLINIK PSIKOFARMAKOLOJİ BULTENİ-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, vol.20, no.4, pp.274-287, 2010 (SCI-Expanded)
- XVII. **Behavioral Disturbances and Depression of Patients with Parkinson's Disease have Significant Impact on Caregivers' Burden and Depression**
Sarandol A., EKER S. S., Sivrioglu E. Y., ÖZKAYA G., Erer S., ZARİFOĞLU M., Kirli S.
NEUROLOGY PSYCHIATRY AND BRAIN RESEARCH, vol.16, pp.91-96, 2010 (SCI-Expanded)
- XVIII. **The Association of the Level of Caregiver Burden with the Sociodemographic Variables and the Characteristics of the Disorder in Schizophrenic Patients**
Aydin A., EKER S. S., Cangur S., SARANDÖL A., KIRLI S.
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, vol.46, pp.10-14, 2009 (SCI-Expanded)
- XIX. **The potential relationship between QTc interval prolongation and ziprasidone treatment: three cases**
Eker S. S., Sarandol A., Akkaya C., Sivrioglu E. Y., Kirli S.
JOURNAL OF PSYCHOPHARMACOLOGY, vol.23, no.8, pp.993-996, 2009 (SCI-Expanded)
- XX. **Effects of adding depot antipsychotic medication to oral antipsychotic regimen on treatment**

compliance in schizophrenic patients.

EKER S. S., AKKAYA C., Cangur S., SARANDÖL A., Deniz G., KIRLI S.

KLINIK PSIKOFARMAKOLOJİ BULTENİ-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, vol.19, no.3, pp.273-278, 2009 (SCI-Expanded)

- XXI. **Factors influencing response and remission in the treatment of major depressive disorder: Can social adaptation be a determinant factor?**
Sivrioglu Y., KIRLI S., AKKAYA C., Eker S. S., ÖZKAYA G.
KLINIK PSIKOFARMAKOLOJİ BULTENİ-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, vol.19, 2009 (SCI-Expanded)
- XXII. **Are there differences between serotonergic, noradrenergic and dual acting antidepressants in the treatment of depressed women?**
EKER S. S., KIRLI S., AKKAYA C., Cangur S., SARANDÖL A.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, vol.10, no.4, pp.400-408, 2009 (SCI-Expanded)
- XXIII. **Addiction to topically used cyclopentolate hydrochloride: A case report**
AKKAYA C., Kocagoz S. Z., SARANDÖL A., EKER S. S., KIRLI S.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol.32, no.7, pp.1752-1753, 2008 (SCI-Expanded)
- XXIV. **Effects of various antidepressants on serum thyroid hormone levels in patients with major depressive disorder**
EKER S. S., AKKAYA C., SARANDÖL A., Cangur S., SARANDÖL E., KIRLI S.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol.32, no.4, pp.955-961, 2008 (SCI-Expanded)
- XXV. **Reboxetine induced erectile dysfunction and spontaneous ejaculation during defecation and micturition**
Sivrioglu E. Y., Topaloglu V. M., Sarandol A., Akkaya C., Eker S. S., Kirli S.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol.31, no.2, pp.548-550, 2007 (SCI-Expanded)
- XXVI. **Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems**
Sarandol A., Sarandol E., Eker S. S., Erdinc S., Vatansver E., Kirli S.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, vol.22, no.2, pp.67-73, 2007 (SCI-Expanded)
- XXVII. **A comparison of the efficacy and tolerability of reboxetine and sertraline versus venlafaxine in major depressive disorder: A randomized, open-labeled clinical trial**
Yazicioglu B., Akkaya C., Sarandol A., Akgoz S., Eker S. S., Kirli S.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol.30, no.7, pp.1271-1276, 2006 (SCI-Expanded)
- XXVIII. **Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder**
Sarandol A., Sarandol E., Eker S. S., Karaagac E. U., Hizli B. Z., Dirican M., Kirli S.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol.30, no.6, pp.1103-1108, 2006 (SCI-Expanded)
- XXIX. **Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: An open label study**
Akkaya C., Sivrioglu E. Y., Akgoz S., Eker S. S., Kirli S.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, vol.21, no.5, pp.337-345, 2006 (SCI-Expanded)
- XXX. **Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder**
Eker S. S., Akkaya C., Akgoz S., Sarandol A., Kirli S.
TURK PSIKIYATRI DERGISI, vol.16, no.3, pp.153-163, 2005 (SSCI)

Articles Published in Other Journals

- I. **Evaluation of the effect of the COVID-19 pandemic on the depression, anxiety and stress levels of anesthesiology and reanimation doctors, and their work and social lives**
SOYLU N. B., MOGOL E. B., EKER S. S., AKESEN S., SOYLU H. S.
Kastamonu Medical Journal (KASMEJ), vol.4, no.2, pp.39-44, 2024 (Peer-Reviewed Journal)
- II. **Successful ECT treatment of a treatment resistant manic bipolar patient with intracranial mass and pulmonary embolism history: Case**
MUŞTUCU A., GÜLLÜLÜ R. A., EKER S. S.
KLINİK PSIKİYATRİ DERGİSİ-TURKISH JOURNAL OF CLINICAL PSYCHIATRY, vol.25, no.4, pp.430-433, 2022 (ESCI)
- III. **Prediction of Depression in Schizophrenia Can serum Levels of BDNF or EGF Help us**
Yavaşçı Öztepe E., EKER S. S., SARANDÖL E., CANGÜR Ş., KIRLI S.
Journal of Psychiatry, 2014 (Peer-Reviewed Journal)
- IV. **Evaluation of psychiatric disorders in Parkinson's disease Parkinson hastalarında psikiyatrik bozuklukların araştırılması**
SARANDÖL A., EKER S. S., SİVRİOĞLU E. Y., ÖZKAYA G., ERER S., ZARİFOĞLU M., KIRLI S.
Yeni Symposium, vol.45, no.2, pp.74-79, 2007 (Scopus)
- V. **Parkinson hastalarında Psikiyatrik Bozuklukların Araştırılması**
SARANDÖL A., EKER S. S., SİVRİOĞLU E. Y., ÖZKAYA G., ERER ÖZBEK Ç. S., ZARİFOĞLU M., KIRLI S.
Yeni Sempozyum Dergisi, vol.45, no.2, pp.74-79, 2007 (Scopus)
- VI. **Comparison of Effects of Sertraline and Reboxetine on the Loss of Social Functioning in Major Depressive Disorder: A Randomized, Open-Labelled Study**
AKKAYA C., SİVRİOĞLU E. Y., SARANDÖL A., EKER S. S., KIRLI S.
DUSUNEN ADAM-JOURNAL OF PSYCHIATRY AND NEUROLOGICAL SCIENCES, vol.19, no.1, pp.5-13, 2006 (ESCI)

Books & Book Chapters

- I. **Şizofrenide eşanlı durumlar**
EKER S. S.
in: ŞİZOFRENİ VE DİĞER PSİKOTİK BOZUKLUKLAR, , Editor, BAYT, pp.116-136, 2018
- II. **The use of Psychotropic Drugs in Renal Diseases**
EKER S. S.
in: PSYCHOTROPIC DRUGS AND MEDICAL CONDITIONS, Faruk Uğuz, Editor, Nova Science Publishers, Inc., New York, pp.141-156, 2017

Refereed Congress / Symposium Publications in Proceedings

- I. **Arilai: a naturalistic open-label study of aripiprazole long acting injectable efficacy on functioning and quality of life in schizophrenia patients**
ALPTEKİN K., ANIL YAĞCIOĞLU A. E., EKER S. S., Yıldız M., Kaymak Ulusoy S., TAMAM L., YAZICI M. K., SOYGÜR H., ÜÇOK V. A.
32nd ECNP, Kopenhag, Denmark, 7 - 19 September 2019
- II. **Theory of mind deficit on remission period of bipolar affective disorder**
AKKAYA C., KILINCEL O., EKER S. S.
18th Annual Conference of the International-Society-for-Bipolar-Disorders / 8th Biennial Conference of the International-Society-for-Affective-Disorders, 13 - 16 July 2016, vol.18, pp.132
- III. **Theory of mind deficit on remission period of bipolar affective disorder**
Akkaya C., Kilincel O., Eker S. S.
18th Annual Conference of the International-Society-for-Bipolar-Disorders / 8th Biennial Conference of the

International-Society-for-Affective-Disorders, Amsterdam, Netherlands, 13 - 16 July 2016, vol.18, pp.132

IV. Attention deficit/hyperactivity disorder comorbid with bipolar disorder does not enhance cognitive impairment

Akkaya C., Gunduz C., Cangur S., Eker S. S.

5th Biennial Conference of the International-Society-for-Bipolar-Disorders, İstanbul, Turkey, 14 - 17 March 2012, vol.14, pp.52

V. PARKİNSON HASTALARINDA DEPRESYONUN HASTALIK ÖZELLİKLERİ İLE İLŞKİSİ

ERER ÖZBEK Ç. S., YILDIZ D., KARLI H. N., ZARİFOĞLU M., EKER S. S., SARANDÖL A., SİVRİOĞLU E. Y., KIRLI S.

Parkinson Hastalığı Hareket Bozuklukları 2005, Turkey, 21 - 23 May 2005

Metrics

Publication: 43

Citation (WoS): 688

Citation (Scopus): 734

H-Index (WoS): 10

H-Index (Scopus): 11

Non Academic Experience

ULUDAĞ ÜNİVERSİTESİ